Business
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
Successful completion of €30 Million capital increase, with strong international demand and oversubscriptionAwarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)Vafidemstat’s Phase III PORTICO-2 trial endpoints for agitation and aggression in BPD defined with input from new Clinical Advisory Board; finalizing preparations for Phase III Results of observational clinical study on Phelan-McDe
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Successful completion of €30 Million capital increase, with strong international demand and oversubscription","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Vafidemstat’s Phase III PORTICO-2 trial endpoints for agitation and aggression in BPD defined with input from new Clinical Advisory Board; finalizing preparations for Phase III ","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Results of observational clinical study on Phelan-McDermid syndrome patients published in Frontiers in Psychiatry","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"First patient dosed in NCI-sponsored Phase I/II study of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer ","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"First cohort dosed in Phase I/II study of iadademstat plus azacitidine in myelodysplastic syndrome","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Continues to recruit patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant acute myeloid leukemia patients","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1055,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a ...